厄达替尼是医保药吗？

Is erdafitinib a medically insured drug? It has not yet been launched in the country, so it has not been included in medical insurance.

   Erdafitinib is the first targeted therapy drug approved by the US FDA for advanced or metastatic urothelial cancer. It regulates cell growth and division by targeting genetic changes in fibroblast growth factor receptor (FGFR) to inhibit tumorigenesis and angiogenesis. Erdafitinib represents the first personalized treatment option for patients with metastatic urothelial cancer who have genetic alterations in FGFR.

Treatment with the oral FGFR inhibitor erdafitinib (ERDA) showed consistent efficacy in patients with locally advanced or metastatic urothelial cancer and FGFR gene mutations after a median follow-up of two years in the BLC2001 phase II clinical trial. The research is a breakthrough for patients with mutations in the FGFR3 gene, which is present in about 15 to 20 percent of patients with metastatic bladder cancer. For decades, the standard treatment for these cancers has been an aggressive form of cisplatin-based chemotherapy - a very powerful drug with significant side effects. In recent years, new checkpoint blockade inhibitors have been approved, however, responses to these immunotherapies are only about 15% to 20%.

At a median follow-up of two years, the therapy resulted in a median OS of 11.3 months and an objective tumor response rate of 40%. Additionally, 12-month and 24-month survival rates were 49% and 31%, respectively, with 31% of patients responding for more than a year. Last year, erdafitinib treatment became the first targeted therapy approved by the US FDA for patients with metastatic bladder cancer. It was well tolerated and could provide patients with a new option after previous treatments were ineffective or intolerable. ERDA (ERDA) appears to be effective in some patients who have failed previous immunotherapy.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: